Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Serna Bio is an AI-driven RNA-targeted drug discovery company building small-molecule translational enhancers and a proprietary platform for identifying druggable RNA structures, designing RNA-focused chemistry, and advancing preclinical programs in hard-to-drug diseases.
Primary product
Serna Bio Discovery Platform for RNA-targeted small-molecule drug discovery
Founded
2021
Headquarters
Widnes, Halton, United Kingdom
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
RNA-targeted drug discovery / AI drug discovery
Offices
0 jobs at Serna Bio
Check back later for new openings
Business model
Stage
seed
Latest round
Seed · Sep 2021
Sep 2021 · Y Combinator
Leadership
Founder & CEO
Chief R&D Officer
Director of ChemAI and Vancouver Site Lead
Head of Platform Biology
Public signals portray a lean, mission-driven biotech culture focused on challenging biology, rapid experimentation, and strong team camaraderie; posts emphasize building at pace, staying frugal, and working toward clinic with a collaborative team.
Compensation
No public salary bands or compensation details were found in the sources reviewed.
Pricing
Partnering and collaboration agreements with success-based payments, development/regulatory milestones, and commercial milestones
Differentiators
Technology
Customers
Competitors
Serna Bio LinkedIn · May 2026
Serna Bio highlighted its latest preprint and said its platform can design RNA-modulating small molecules from the ground up, including reported potency and expression improvements in a translational enhancement program.
bioRxiv · May 2026
Serna Bio published a preprint describing its GenAI chemistry platform for RNA-targeting small molecules, including benchmark results versus public generative models and experimental validation of designed compounds.
Chiesi Group · Jul 2025
Serna Bio entered a global discovery collaboration with Chiesi Group to find RNA-targeting small molecules for respiratory disease. The deal uses Serna Bio's proprietary platform, includes success-based and milestone payments, and gives Chiesi an option to acquire resulting assets.
PR Newswire / Serna Bio · Jan 2025
The company announced a Scientific Advisory Board and described its platform as a preclinical AI-enabled RNA-targeting small-molecule discovery engine focused on translational enhancement, neuro-metabolism, and obesity.